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The study of extracellular vesicles (EVs) in cancer progression is a complex and rapidly evolving field. Whole categories of cellular
interactions in cancer which were originally presumed to be due solely to soluble secreted molecules have now evolved to include
membrane-enclosed extracellular vesicles (EVs), which include both exosomes and shed microvesicles (MVs), and can contain
many of the samemolecules as those secreted in soluble form but many different molecules as well. EVs released by cancer cells can
transfer mRNA, miRNA, and proteins to different recipient cells within the tumor microenvironment, in both an autocrine and
paracrinemanner, causing a significant impact on signaling pathways, mRNA transcription, and protein expression.The transfer of
EVs to target cells, in turn, supports cancer growth, immunosuppression, andmetastasis formation.This review focuses exclusively
on breast cancer EVs with an emphasis on breast cancer-derived exosomes, keeping in mind that breast cancer-derived EVs share
some common physical properties with EVs of other cancers.
1. Introduction
Breast cancer is the most prevalent type of cancer in women
[1]. Although a multitude of treatment options are avail-
able [2–4], approximately one-third of women worldwide
diagnosed with breast cancer still die from the disease,
largely frommetastasis, especially brainmetastasis [5–8]. EVs
have been hypothesized to have significant roles in breast
cancer growth and metastasis and thus have been evaluated
as potential avenues of new therapeutic intervention. EVs,
including exosomes and MVs, are secreted in large quan-
tities by cancer cells into the local microenvironment and
premetastatic “niche” [9].While both exosomes andMVs are
small (usually < 1 𝜇m in diameter), these bilipid membrane-
enclosed vesicular structures [10–13] have a distinct biogen-
esis: exosomes are generated through inward budding of an
endosome resulting in a multivesicular body (MVB) which is
released by subsequent fusion of the MVB with the plasma
membrane [14–18], whereas MVs are released directly by
budding from the cellular plasma membrane [15, 18, 19].
However, EVs including both MVs and exosomes have been
proposed to enter target cells through multiple mechanisms,
including ligand-receptor-mediated [20, 21], or lipid raft-
mediated entry [22, 23], with EV fusion and uptake greatly
influenced by surrounding pH levels [24]. Exosomes are
typically smaller than MVs, being 100 nm or less in diameter,
while the latter are > 100 nm in size. Some size overlap does
exist, however [25–29]. Apoptotic bodies, another type of EV,
are poorly characterized and not generally included within
the general categories of exosomes or MVs and therefore will
not be discussed in this review.This review will discuss breast
cancer EV purification, composition, and effect on target
cells within the tumor microenvironment to promote cancer
growth and metastasis, as well as their possible use as drug
delivery vehicles of anticancer therapeutic drugs.
2. Breast Cancer EV Characterization and
Proteomic Profiling
2.1. Methods of Isolation. There are several variations to the
method of isolating MVs and exosomes from cell culture
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supernatants, but most involve differential centrifugation at
various speeds to separate particles based on size and density.
For EV isolation, cells are grown in media supplemented
with exosome-depleted fetal bovine serum (FBS). The first
step in purification involves a low-speed centrifugation at
300×g–500×g for 5–10min to remove live cells [30–32].
The supernatant is then centrifuged at 1200×g–2000×g for
10–30min to remove dead cells and apoptotic blebs [30,
33–35]. This is followed by centrifugation at 10,000×g for
30min to remove cellular debris [30, 36]. To isolate the
exosome and MV fractions, the supernatant then undergoes
ultracentrifugation at 100,000–200,000×g for 60–120min
[30, 32, 36–38]. The supernatant at this point is discarded
and the pellet, containing exosomes and MVs, is washed
in phosphate buffered saline (PBS) and ultracentrifuged one
final time [30, 36, 39, 40]. The PBS is gently decanted and
the exosome/MV pellet is resuspended in a small volume of
buffer [35, 41]. If human or mouse serum is used as starting
material, an intermediate step using a 0.22 𝜇m filter can be
employed to supplement the centrifugation steps, resulting in
an enrichment in exosomes and smallMVs [32, 38, 42].These
methods have been used to isolate MVs and exosomes from
both cancer and noncancerous cell lines, including LNCaP
prostate cancer, vascular smooth muscle cells (VSMCs), BV-
2, HCMEC/D3, and several breast cancer cells (MDA-MB-
231, MCF-7, and MDA-MB-435) [30, 31, 34, 43]. Exosomes
purified using this methodology are suitable for liquid
chromatography-mass spectrometry (LC-MS) analysis [30,
36]. However, in order to obtain a density-based purer
fraction devoid of additional nonspecific proteins and protein
aggregates, the exosomal/MV supernatant can be layered on
a sucrose gradient prior to high-speed ultracentrifugation
[33, 44]. It is really not possible to separate exosomes from
MVs by strictly physical means.
2.2. Size Variation. Scanning electronmicroscopy (SEM) and
transmission electron microscopy (TEM) have been used to
determine the physical properties of EVs frommany sources,
including cancer and noncancerous cell lines, as well as from
patients with a myriad of diseases. In general, exosomes are
30–100 nm in size and have a characteristic round or cup-
shape, while microvesicles are larger, approximately 100 nm–
1 𝜇m, and are composed of a round-shaped, heterogeneous
population; however, as previously mentioned, a certain
degree of size overlap occurs [11, 35, 40, 42, 44–51]. It is
important to note that the cup-shape appearance of exosomes
visualized by electron microscopy may be an artifact of the
fixation process, and their true shape mirrors that of round
microvesicles [17]. In addition, there is also some variation
in size of EVs based on the method of visualization. For
example, exosomes derived from metastatic MDA-MB-231
breast cancer cells were determined to be 40–120 nm in size
by SEM and contained the typical exosomal marker CD63
[52]. EVs shed from MDA-MB-231 cells, on the other hand,
were larger in size and determined to be 57–440 nm in size
with amean diameter of 121± 54 nmby TEM [53]. As another
example, tissue factor (TF) antigen has also been identified
in breast cancer-derived EVs [53, 54]. 10% of MDA-MB-231-
derived MVs were found to express TF, and although EVs up
to 220 nm contained active TF, most EVs containing active
TF were 100 nm or smaller [53]. In an independent study, TF
was instead found in breast cancer MVs 200–350 nm in size.
[54]. The term “exosome-like vesicles” (ELV) has been used
in some studies to describe vesicles with relatively small size
and similar densities, physical characteristics, and protein
expression patterns as exosomes [55]. For example, in one
study, ELVs fromMDA-MB-231 cells were 20–180 nm in size,
with the majority being 40–100 nm in size, and contained
particles that were both round and cup-shaped [56]. By TEM,
ELVs from MCF-7 and MDA-MB-231 cells were reported by
Kruger et al. [57] to be 80–200 nm in size and round in shape.
For the purpose of this review, ELVs will be referred to as
exosomes. Nanoparticle tracking analysis (NTA) is another
technique frequently used to determine the concentration
and size of EVs [35, 37, 58]. For example, Zheng et al.
used NTA to examine Rab27-dependent exosome secretion
fromMDA-MB-231 cells [37]. NTA analysis determined peak
exosome size to be 129 nm, while an average of 79 nm was
determined by TEM.
2.3. EV Proteins as Cancer Markers. Cancer cell lines are
known to secrete significantly more EVs than noncancerous
cell lines [59–63]. In line with this, serum from breast
carcinoma (BrCa) patients contained significantly higher
levels of exosomes than healthy donors [41, 64, 65]. Several
EV proteins are differentially expressed in certain stages and
types of breast cancer and may be used as diagnostic markers
of cancer progression or as a diagnostic marker, that is,
“liquid biopsy” for general cancer diagnosis. For example, the
oncogenic cancer marker CD24 [66] was uniquely expressed
in serum-derived exosomes from BrCa patients [65]. In an
independent study, FAK and EGFR, which are overexpressed
in cancer [67, 68], were significantly higher in MVs from
BrCa patients compared to healthy donors and were found
to be differentially expressed depending on the stage of
cancer [41]. Survivin-2B, a splice variant of the native protein,
which is an apoptosis inhibitor and associated with decreased
survivability [69], has also been identified in EVs from BrCa
patient serum, and the protein expression is lost with the
progression of the disease [70]. In addition to CD24, FAK,
EGFR, and Survivin, BrCa serum EVs have been found to
contain the disintegrin andmetalloprotease ADAM10, as well
as the tetraspanin CD9 [41, 65, 70], with the latter being a
known functional integrin binding partner in breast cancer
cells [71, 72] and a molecular marker of EVs. Similarly to EVs
from serum, exosomes fromBrCa pleural effusions contained
ADAM10, CD9, and CD24 but also contained the epithelial
cell adhesion molecule (EpCAM) [65], a highly expressed
protein on cancer cells [73]. It should be considered, how-
ever, that CD9 is present on EVs of both neoplastic and
nonneoplastic origin [74]. HSP70 and Annexin-1, the latter
of which regulates apoptosis and inflammation [75], were
also identified from BrCa pleural effusion-derived exosomes
[65]. In addition to BrCa patient samples, several EV proteins
have been identified from immortalized cancer cell lines. In
one particular study, the tumor marker extracellular matrix
metalloproteinase inducer EMMPRIN [76, 77] was identified
on SKBR3 and MCF-7 breast cancer-derived MVs, but not
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on exosomes [78]. On the other hand, the tetraspanin CD63,
a binding partner of integrins and tumor marker whose
expression inversely correlates with cancermetastasis [71, 79–
84], and tumor susceptibility gene 101 (TSG101), which is
a subunit of the endosomal sorting complex required for
transport-1 (ESCRT-1) [85], were present almost exclusively
on exosomes [78]. Others have reported CD63, ALG-2-
interacting protein X (Alix), which is involved in exosome
biogenesis and endosomal sorting [86, 87], and TSG101, or
a combination of these proteins, from MDA-MB-231, MCF-
7, T47D:A18, and Hs-578T breast cancer-derived exosomes
[37, 45, 49, 50]. Lysosome-associatedmembrane glycoprotein
1 (LAMP1) and heat shock cognate 70 (HSC70) were also
both found to be in exosomes from MDA-MB-231 cells [56].
Therefore, specific proteins can be used to distinguish breast
cancer exosomes from shed MVs.
2.4. Proteomic Profiling. There has been extensive proteomic
characterization performed on exosomes from breast cancer
cells by liquid chromatography-mass spectrometry (LC-MS).
This proteomic characterization demonstrated that exosomal
content is diverse in nature and varies depending on the cell
line from which they originate. They also contain cytosolic
as well as membrane proteins involved in signaling pathways
and maintenance of cellular structure. In a study performed
by Palazzolo et al., LC-MS identified 32 proteins more
abundant in the MDA-MB-231 exosomes compared with the
cell lysates [56]. These included cytoskeletal proteins such as
cytokeratin 9 (K1C9), tropomyosin 4 (TPM4), and transgelin
2 (TAGL2), proteins regulating cell death, including perox-
iredoxin 2 (PRDX2), Annexin A5, and heat shock protein 71
(HSP71), and signal proteins such as integrin 𝛼6 and integrin
𝛼3 [56]. The latter two proteins are involved in cell migration
and therefore play a role in the growth and angiogenesis
of tumors [88–93]. Exosomes were also enriched in the
beta chain of MHC Class I molecules (B2MG), supporting
the involvement of exosomes in altering immune system
recognition to promote cancer growth [56]. Consistent with
this result, proteomics performed on exosomes from a pleural
effusion of a breast cancer patient identified MHC Class I
molecules, in addition to B-cell translocation gene 1 (BTG1)
and pigment epithelium-derived factor (PEDF) [44]. Since
the decrease in tumor surface expression of BTG1 and
PEDF has been associated with increased cancer growth and
metastasis [94–96], tumor cell exosomal shedding of these
proteins obviously decreases the cell surface content of these
molecules, which benefits the tumor. Secretome profiling
of BT-474 and SKBR3 breast cancer cell lines also showed
that exosomes were enriched in proteins associated with
antigen processing/presentation, such as heat shock 70 kDa
protein 5 (HSPA5), calreticulin (CALR), and proteasome
activator complex subunit 2 (PSME2), and proteins asso-
ciated with glycolysis/gluconeogenesis, such as triosephos-
phate isomerase 1 (TPI1) and phosphoglycerate mutase 1
(PGAM1) [97]. Proteomics of MCF-7 exosomes showed they
contained lipid raft proteins (G protein) and raft-associated
proteins (profilin II, HSP27) [36], giving insight into the
composition of their exosomal membranes. Others have
also documented flotillin-1 and cofilin, proteins associated
with lipid rafts in MCF-7 exosomes [45]. Villarreal et al.
demonstrated exosomes composed a portion of the MCF-
7 and MDA-MB-231 secretomes, and the former included
CD63, along with intracellular proteins such as Annexins
A2 and A4, and a variety of histones and chaperones [98].
Immunoblotting also showed BT-549 breast cancer exosomes
containedAnnexinsA2 andA6 [99]. A separate study showed
BT-549 exosomes were taken up through lipid raft domains,
which possibly involves Annexin A2 in the target cell, while
Annexin A6 may play a role in the movement of exosomes
to the late endosomal compartment [22]. Recently, LC-
MS/MS was used to compare proteins of exosomes from
both MDA-MB-231 and MCF-7 cells [57]. MDA-MB-231-
derived exosomes contained significantly more extracellular
matrix proteins than those from MCF-7 cells [57]. MDA-
MB-231-derived exosomes also containedmore proteins with
catalytic activity, while MCF-7 exosomes contained more
nucleic acid binding and transport proteins [57]. Annexin
A1 was exclusive to MCF-7 exosomes while EpCAM was
exclusive to MDA-MB-231-derived exosomes and both con-
tained Annexin A2 and 𝛼-enolase [57], the latter of which
has been shown to promote cancer cell growth, migration,
and metastasis [100]. MDA-MB-231- and MCF-7-derived
exosomes also differentially expressed certain miRNAs. For
example, MDA-MB-231-derived exosomes had higher levels
of tumorigenicmir-130a andmir-328, while those fromMCF-
7 cells had higher levels of mir-301a [57], the expression of
which indicates a negative prognosis of patients with invasive
ductal or triple negative breast cancer [101, 102]. Therefore,
exosomes from both breast cancer cell lines contain proteins
and miRNA that are oncogenic in nature, yet they each have
their own distinctive identifying markers that may relate
to the nature and aggressiveness of the cancer type. Both
breast cancer-derived exosomes andMVs contain significant,
yet distinctive proteins related to breast cancer progression
and metastasis (Table 1). Additional breast cancer-derived
exosomal proteins have functional roles in immune evasion
and miRNA biogenesis and serve as surrogate metastatic
markers (Table 2).
3. Visualization of Breast Cancer EVs
Direct visualization of breast cancer EV release and uptake in
both live and fixed cells by microscopy has been facilitated
by fluorescently tagged EV proteins, fluorescent antibodies
or peptides, or lipid fluorescent dyes. In particular, several
groups have utilized breast cancer cell lines overexpressing
the exosomal marker CD63 with a green fluorescent protein
(GFP) fusion tag [22, 46, 103]. A striking example is shown
by Suetsugu et al., who engineered MDA-MB-231 and mouse
mammary tumor (MMT) cells stably expressing CD63-GFP
[103]. From these cell lines, the transfer of CD63-GFP exo-
somes to nonfluorescent autologous breast cancer cells was
visualized in vitro and in xenograft models. Upon injection
into immunodeficient mice, breast cancer cells expressing
CD63-GFP formed tumors that metastasized to the lungs,
secreting fluorescent exosomes into both the primary tumor
and metastatic microenvironment. Various studies have also
utilized PKH dyes, which intercalate with lipids, [32, 52, 104,
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105], or fluorescent antibody or peptidemarkers [43, 106, 107]
to stainMVs and exosomes, demonstrating that breast cancer
EVs can transfer nucleic acids and proteins to autologous
and heterologous cells within the tumor microenvironment,
possibly resulting in the acquisition of the cancer phenotypes,
favoring tumor progression, immune evasion, andmetastasis.
4. Horizontal Transmission of
miRNA and Proteins
EVs purified from breast cancer cells typically carry specific
mRNAs andmiRNAs in addition to proteins and can transfer
both transcripts and intact proteins to surrounding cancer
cells to promote tumor development. In fact, miRNA is
enriched in exosomes derived from the breast cancer cell
lines 4T.1, MDA-MB-231, and MCF-7 compared to exosomes
from normal breast cells MCF10A and NMuMG [64]. Exo-
somes from metastatic cell lines (MDA-MB-231 and 4T.1)
were also enriched in miRNA compared to exosomes from
nonmetastatic cells (MCF-7) [64]. miRNAs were found to
be secreted into subpopulations of MVs from MDA-MB-231
cells, with different miRNAs packaged into different types
of vesicles [48]. Addition of MVs from MDA-MB-231 cells
caused an increase in total RNA in human submandibular
gland (HSG) cells [108]. In turn, HSG MVs isolated from
HSG cells that were treated with MDA-MB-231-derived MVs
contained multiple new mRNAs and an increase in protein
levels [108]. Cancer cell-derived exosomes are capable of
miRNA processing and biogenesis in addition to transfer of
miRNA to target cells [64].This is evidenced by the detection
of proteins involved in miRNA biogenesis, including the
RISC loading complex (RLC) proteins Dicer, Ago2, and
TRBP, in exosomes from breast cancer cell lines and patient
samples but not from normal breast cell lines [64].
5. Induction of Drug Resistance
Several mechanisms have been described for breast cancer
EV-mediated transfer of drug resistance to promote tumor
growth and progression. One such mechanism involves
the transfer of P-glyoprotein (P-gp), a protein known to
be involved in drug resistance [109, 110], through MVs
produced from doxorubicin- or docetaxel-resistant breast
cancer cells into target endothelial or drug-sensitive cancer
cells [111, 112]. These MVs also transferred TrpC5, which
caused activation of the NFATc3 transcription factor to
stimulate transcription of P-gp mRNA [111]. In addition to
the transfer of proteins, the transfer of miRNAs from drug-
resistant breast cancer-derived exosomes conferred drug-
resistant properties to target cells [47, 104]. Specifically,
exosomes from docetaxel-resistantMCF-7 cells containmiR-
NAs which downregulate mRNA encoding chemosensitive
properties when transferred to nonresistant MCF-7 cells
[47, 104]. Exosomes from doxorubicin-resistant MCF-7 cells
also induced chemoresistance in nonresistant MCF-7 cells
through transfer of miRNAs [47]. In another study, exo-
somes produced from tamoxifen-resistant MCF-7 cells were
taken up by MCF-7 wild type cells and released miR-
221/222 [32]. miR-221/222 subsequently caused a decrease
in P27 and ERa (targets of miR-221/222) protein levels,
which caused an increase in tamoxifen resistance in MCF-
7 target cells. Besides conferring drug resistance, cancer
exosomes can decrease the effectiveness of the therapeutic
drug trastuzumab, an antibody that binds HER2 [40]. The
presence ofHER2 on cancer cells is linked to increased cancer
metastasis and tumor proliferation [113, 114]. Exosomes from
SKBR3 and BT-474, both of which are HER2-overexpressing
breast cancer cell lines, contain active HER2 and, along with
exosomes from HER2-positive breast cancer patient serum,
bound to trastuzumab to decrease the drugs’ effectiveness
at inhibiting SKBR3 cell proliferation [40]. Treatment of
BT474 cells with epidermal growth factor (EGF) and hereg-
ulin (HRG), which are growth factors secreted by cancer
cells [115–117] and activators of HER2 [118, 119], caused a
significant increase in exosome production [40], leading to
the possibility that enhanced secretion of exosomes may be
a way for the tumor microenvironment to support cancer
growth in the presence of therapeutic agents. Consistent with
these results, HER2+ exosomes from BT-474 and SKBR3
cells decreased the trastuzumab-induced cytotoxic effects of
peripheral blood mononuclear cells (PBMC) against BT-474
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cells [120]. Besides the transfer of proteins and miRNA to
cancer cells, breast cancer EVs can also directly secrete the
anticancer drug doxorubicin [121]. The number of secreted
MCF-7-derived EVs positively correlated with increasing
drug concentration, which suggested EV release is a direct
mechanism for imparting chemoresistance within a tumor
[121].
6. Therapeutic Implications of EVs
It is possible to take advantage of the drug delivery capabilities
of exosomes for breast cancer therapy, as shown by Tian
et al. [122]. Doxorubicin, incorporated into exosomes from
immature dendritic cells (imDC) and taken up by both
MDA-MB-231 and MCF-7 cells, caused an inhibition of
cell proliferation. When injected into nude mice implanted
with MDA-MB-231 tumors, it caused a reduction in tumor
growth [122]. Specific targeting to tumors was achieved
by incorporating an RGD integrin target sequence in the
exosomes which bound to MDA-MB-231 cells, which nat-
urally express high levels of integrin 𝛼v [123]. Exosomes
from HEK293 cells stably expressing EGF or EGFR peptide
have also been studied as therapeutic agents by targeting
breast cancer cells expressing high levels of EGFR (such
as the HCC70 breast carcinoma cell line) [39]. The tumor
suppressor let-7a miRNA was transfected into HEK293 cells
expressing EGFR peptide, and exosomes produced from
these cells significantly decreased HCC70 tumor growth in
mice [39]. Additionally, treatment of 4T.1 murine breast
cancer cells with epigallocatechin gallate (EGCG), a chemical
with antitumor effects, caused an increase in the levels of
the tumor suppressor miR-16 within exosomes [124]. Exo-
somes from EGCG-treated breast cancer cells subsequently
decreased NF𝜅𝛽 activity and M2 polarization in tumor-
associated macrophages (TAM) through miR-16 [124]. M2
macrophages, which inhibit inflammation during the end
stages of inflammatory processes such as wound healing
[125], are known to have tumor-promoting phenotypes [126,
127]. Consequently, therapeutic agents can induce transfer
of tumor suppressors to surrounding macrophages through
exosomes to decrease their cancer-associated properties.
7. EVs as Immunomodulators
Many groups have studied the immunosuppressive effects
of tumor-derived EVs and their relation to cancer pro-
gression within the tumor microenvironment (Figure 1).
In one study, MVs from 36% of breast cancer patients
contained indoleamine 2,3-dioxygenase (IDO), an enzyme
that has a role in immunosuppression and tumor survival
[128]. Another example of exosomal-mediated immunemod-
ulation was described in a study involving TS/A murine
mammary tumor-derived exosomes, which were found to act
as immune system suppressors to promote tumor progression
by inhibiting the differentiation of myeloid precursors in the
bone marrow into dendritic cells, partially through induc-
tion of IL-6 mRNA [129]. Myeloid-derived suppressor cells
(MDSCs) are involved in tumor growth, partially through
the inhibition of T-cell activation via Toll-like receptor
(TLR) adaptor protein MyD88 [130]. Murine melanoma-
derived exosomes were found to exacerbate the effects of
MDSCs, which included the induction of the proinflam-
matory cytokine CCL2 through MyD88 [131]. This same
study also discovered that 4T.1-derived exosomes caused an
increase in lung metastases through CCL2 [131]. Similarly,
breast cancer TS/A-derived exosomes injected into a mouse
model caused an increase ofMDSCs within both the primary
tumor and the spleen [132]. Breast tumor-derived exosomes
have also been found to reduce the immune response by
inhibiting NK cytotoxicity. In one case, TS/A and 4T.1
breast tumor-derived exosomes inhibited activated NK cell
proliferation and prevented them from killing TS/A and 4T.1
tumor cells [133].
In another study, injection of TS/A tumor-derived exo-
somes into the general circulation of mice decreased the
cytotoxicity of NK cells by reducing the percentage and
activity of NK cells [105]. TS/A-, 4T.1-, and MDA-MB-
231-derived exosomes also decreased stimulated NK cell
proliferation, and mice implanted with TS/A or 4T.1 tumors
and treatedwith TS/A or 4T.1 breast tumor-derived exosomes
had more rapid tumor growth and metastases compared to
controls [105]. The human MHC Class I chain-related genes
MICA and MICB are ligands of the NKG2D receptor and
stimulate the immune response by activating T-cells [134–
137]. To evade detection by the immune system, MDA-MB-
231-derived exosomes lack MICA or MICB and therefore
there is no immune stimulation [138]. Furthermore,ADAM17
in MDA-MB-231 breast cancer cells cleaves MICA/MICB
from the cell surface of the cancer cell to produce a sol-
uble form, sMICA/sMICB, which may result in a type of
immune decoy [138]. Exosomes fromT47D breast carcinoma
cells decreased the amount of NKG2D-positive lymphocytes
within peripheral blood lymphocytes (PBL), which was
modulated through NKG2D ligands such as MICB, CD81,
and MHC Class I on exosomes [33]. These T47D-derived
exosomes also led to inhibition of the cytotoxic function of
CD8+ T-cells, which may be related to the downregulation
of NKG2D [33]. This could be yet another mechanism for
cancer to evade and/or inhibit the host immune system.
A study by Deng et al. showed exosomes isolated from
the 4T.1 breast cancer cell line that had interacted with
immunosuppressive leukocytes from the tumor microenvi-
ronment conferred properties that enhanced tumor metas-
tasis through production of MMP-9 and proinflammatory
cytokines [139]. One interesting study suggested how the
structural interactions of MDA-MB-231- andMCF-7-derived
MVs with human beta-defensin 6 (hBD6), a class of proteins
with antimicrobial activity [140], were linked to metastatic
potential [141]. There were more nuclear magnetic resonance
(NMR) chemical shifts and larger resonance intensity ratios
associated with MCF-7-derived MVs compared to MDA-
MB-231-derived MVs upon association with hBD6, which
indicated stronger binding to the MCF-7-derived MVs [141].
This group proposed the weaker interaction of MDA-MB-
231-derived MVs with hBD6 could suggest a greater capa-
bility of evading immune detection and one explanation
for the increased metastatic properties of this cell line
[141].
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Figure 1: Schematic of the numerous interactions between breast tumor-derived EVs and stromal, epithelial, and immune cells within the
tumor niche and the resulting changes that enhance cancer growth andmetastasis. Breast cancer cells avoid detection from the immune system
through EV-mediated decrease in the cytotoxicity of NK and T-cells and secretion of proinflammatory cytokines from macrophages. Tumor
EVs enter fibroblasts and stimulate proangiogenic ERK and AKT kinase activation. Concurrently, EVs cause the secretion of oncogenic
cytokines TGF𝛽 and VEGF in mesenchymal stem cells. Additionally, tumor EVs enter surrounding cancer cells to upregulate signaling
pathways that promote growth and metastasis, including increases in coagulation, adhesion, and a decrease in levels of tumor suppressors.
To promote invasion, EVs induce epithelial cells to secrete growth factors and cause destruction of endothelial vascular structures, thus
enhancing tumor growth.
8. EV Contribution to Breast Tumor
Growth and Metastasis
8.1. EV Transfer of Cancerous Phenotypes. As mentioned
above, cancer cell-derived EVs contain a number of onco-
genic proteins and miRNAs, which can be transported to
surrounding cancer cells to elicit phenotypic changes within
target cells. Several groups have investigated the mecha-
nisms through which breast tumor-derived EVs upregulate
prometastatic pathways after entering nearby cancer cells.
One scenario involves breast cancer MVs increasing cancer
cell invasion through extracellular matrix metalloproteinase
inducer- (EMPRINN-) dependent phosphorylation of p38
[42]. MDA-MB-231-derived MVs also contain RhoA and
RhoCGTPases, which are upregulated in cancer and involved
in invasion and metastasis [142, 143], as well as ADP-
ribosylation factor 1 (ARF1), which is associated with MV
release and MMP-9 activity within MVs [144]. MMP-9 is
involved in the degradation of extracellular matrix, a critical
step in cancer cell invasion [145, 146]. MDA-MB-231-derived
MVs have also been reported to transfer TF to MCF-7 cells
to cause increase in procoagulant activity [147], which has
been correlated with increased metastatic capabilities [148].
Cellular adhesion is also known to be important in the growth
and metastatic progression of cancer cells [149, 150]. To
this end, the uptake of exosomes derived from BT-549 cells
into target cancer cells caused increased cellular adhesion
and spreading through histone H2A binding to heparin
sulfate proteoglycans [46]. Another study by Melo et al. [64]
highlighted the importance of exosomal miRNA processing
in tumor growth. This group showed that breast cancer exo-
somes have all the components required for cell-independent
processing of pre-miRNAs into mature miRNAs. By treating
normal breast cells with exosomes from metastatic breast
cancer cells and measuring miRNA changes within the target
cell, they showed that exosomal miRNAs have the ability to
alter the transcriptome of target cells. Similarly, treatment
of MCF10A cells with MDA-MB-231-derived exosomes led
to upregulation of miRNAs involved in cancer metastasis,
resulting in downregulation of proteins including PTEN
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and HOXD10, as well as increases in MCF-710A viability,
proliferation, and colony formation, all processes in which
the capability of miRNA biogenesis was essential. MDA-
MB-231-derived exosomes injected with MCF10A cells also
caused tumor growth in nude mice, which was decreased
whenmiRNAbiogenesis within exosomeswas inhibited [64].
Therefore, cancer growth is influenced by miRNA biogenesis
in exosomes. In addition to miRNA, exosomes can also
transfer cancerous properties to heterologous cancer cells to
promote tumor aggressiveness and metastasis. O’Brien et al.
demonstrated that exosomes isolated froman invasive variant
of triple negative breast cancer (TNBC) cells (Hs578Ts
(i)8)
caused an increase in the growth rate, migration, and invasive
capacity of SKBR3, MDA-MB-231, and HCC1954 breast
cancer cell lines, as well as causing an increase in endothelial
cell angiogenesis [50]. Galindo-Hernandez et al. reported
that an epithelial-mesenchymal transition-like process was
induced in MCF10A cells by EVs isolated from plasma of
women with breast carcinoma [151]. Exosomes from the
serum of patients with TNBC also produced significantly
greater invasion of breast cancer cell lines compared to
exosomes from healthy donors [50]. Recently, using a TNBC
xenograft model of inflammatory breast cancer (MARY-
X) [152], a model which forms tight tumor cell aggregates
(termed spheroids) in vitro, which represent the in vivo
equivalent of lymphovascular tumor emboli, complete exo-
somal biogenesis could be observed by TEM (Figure 2). In
this model, large numbers of secreted exosomes observed
within the intercellular space between cancer cells suggest
the possibility that important exosomal-mediated autocrine
signaling occurs in actual tumor emboli whichmay give them
a survival advantage (unpublished observations). Since most
breast cancers are adenocarcinomas, which are present in
both metastatic sites and the circulation as circulating tumor
cells (CTCs), this exosomal-mediated autocrine signaling
may have wide therapeutic implications.
8.2. Hypoxic Effects on EV-Influenced Metastasis. Cancer
cells have a unique ability to survive and grow under
hypoxic conditions [153]. Exosome secretion plays a role in
the ability of tumors to metastasize under limited oxygen
conditions. Hypoxic conditions are known to increase MV
and exosome release from a variety of breast cancer cell
lines, including MCF-7, MDA-MB-231, and SK-BR3 [43, 45],
which requires hypoxia-inducible factor- (HIF-) dependent
RAB22A expression [43]. Hypoxic breast cancer-derived
MVs caused increases in tumor metastasis and invasion,
which were dependent on the expression of RAB22A within
the MVs [43]. A low pH often accompanies hypoxia in
cancerous phenotypes [154], and it has been previously
reported that melanoma-derived exosome secretion and
uptake increases with decreased pH levels [24]. Additional
studies showed that theMCF-7 breast cancer cell line became
more resistant to the chemotherapeutic drug cisplatin at
lower pH levels [155], and treatment of metastatic breast
cancer patients with proton-pump inhibitors (PPI) led to
enhanced efficacy of chemotherapy [156]. From these results,
it can be proposed that treatment of breast carcinomas with





Figure 2: Early biogenesis of exosomes present within a multivesic-
ular body (MBV) of the MARY-X spheroids is depicted. The MBV
will subsequently fusewith the plasmamembrane and exosomeswill
be released from the cell.
tumor microenvironment, leading to enhanced chemosen-
sitivity. Breast cancer-derived exosomes produced under
hypoxic conditions can also promote inflammatory cross
talk within the tumor niche to promote growth, which is
decreased by activation of nuclear receptors within the cancer
cell [157]. This leads to the possibility of nuclear receptors as
new therapeutic targets, whose efficacy can be increased by
taking advantage of the exosome-mediated delivery system
between cancer cells.
8.3. Effects on the Tumor/Metastatic Niche. Breast tumor
exosomes have the ability to prime the premetastatic niche,
which involves the transfer of proteins and activation of
signaling pathways within epithelial cells, stromal cells,
macrophages, and fibroblasts that promote tumor progres-
sion (Figure 1). Several studies have demonstrated that exo-
somes from cancer cells have this effect on the surrounding
microenvironment. MVs derived from MDA-MB-231 have
been shown to confer cancerous phenotypes to NIH 3T3
fibroblasts as well as noncancerous MCF10A human breast
epithelial cells, including increased survival and cellular
transformation, partly through the transfer of tissue transg-
lutaminase (tTG) [107]. MDA-MB-231-derived MVs caused
NIH 3T3 tumor growth in nude mice through activation
of AKT and ERK kinases in NIH 3T3 fibroblast cells,
requiring tTG [107]. In another example, MDA-MB-231-,
T47DA18-, and MCF-7-derived exosomes were taken up by
human primary mammary epithelial cells (HMEC), causing
an increase in reactive oxygen species (ROS) and secretion
of tumor growth factors from HMECs [49]. Increases in
ROS by breast cancer-derived exosomes led to upregulation
of autophagy through an increase in the phosphorylation
of DNA damage response proteins (DDR) (ATM, H2AX,
and Chk1) and p53 stabilization [49]. Autophagy, which is
the internalization of damaged material within a cell, is an
important survival mechanism for cancer cells to acquire
energy to keep up with the demands of tumor growth [158].
In addition, cancer exosomes caused an increase in HMEC
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autophagy in part by transferring LC3 proteins, involved in
autophagosome cargo sorting [159], to HMEC cells [49]. A
study done by Cho et al. indicates that breast tumor-derived
exosomes can differentiate mesenchymal stem cells (MSC)
into tumor-associatedmyofibroblasts [160], which are known
to contribute to tumor growth, progression, and metastasis
within the tumor microenvironment [161]. In particular,
MDA-MB-231- and MCF-7-derived exosomes increased the
expression of𝛼-SMA,which is an indicator ofmyofibroblasts,
through the activation of SMAD2-dependent pathways, and
cytokines such as TGF𝛽 and VEGF, which support tumor
growth, when added to adipose-derived mesenchymal stem
cells (ADSC) [160]. Metastatic enhancement of breast cancer
cells is regulated through exosomalmiR-105, which can target
tight junctions in primary human microvascular endothelial
cells (HMVEC), resulting in the increased permeability of
cell monolayers, the destruction of vascular structures, and
induced HMVEC migration [162]. Additionally, treatment
of HMVECs withMDA-MB-231-derived exosomes increased
transendothelial migration of MDA-MB-231 cells through
HMVEC monolayer, and mice pretreated with MDA-MB-
231-derived exosomes and then injected with MDA-MB-231
cells had increased lung and brain metastases [162]. MDA-
MB-231-derived exosomes can also transfer miR-10b, which
is more highly expressed in exosomes from metastatic as
opposed to nonmetastatic cell lines, to immortalized human
mammary epithelial (HMLE) cells to reduce levels of the
tumor suppressor HOXD10 [163] protein and subsequently
increase cell invasion [52]. Inflammation from macrophages
promotes tumor growth and metastasis to distant sites [164,
165]. Concurrently, macrophages treated with breast cancer-
derived exosomes caused significant increases in NF-𝜅𝛽 acti-
vation and production of inflammatory cytokines (including
IL-6 and TNF𝛼) compared to exosomes from normal breast
cells through exosomal binding to the Toll-like receptor 2
(TLR2) [106]. Additionally, MDA-MB-231 cells transplanted
into immunodeficient mice released exosomes that entered
distant macrophages in lymph nodes, causing increases in
IL-6 expression [106]. This showed breast cancer exosomes
can alter macrophage phenotypes to cause an increase in
metastasis. In another study, MCF-7-derived EVs transferred
Wnt 5a mRNA, which plays an important role in tumor
invasion, to macrophages, where it was translated into Wnt
5a protein [78].ThisWnt 5a protein inmacrophages was then
packaged into EVs and secreted from cells. The macrophage
EVs containing Wnt 5a subsequently caused an increase in
MCF-7 cell invasion [78]. Therefore, breast cancer EVs can
transfer mRNA tomacrophages, which can, in turn, translate
and package cancerous proteins into vesicles, which are then
subsequently secreted into the tumor microenvironment to
enhance the invasive capacity of surrounding cancer cells in
a paracrine manner.
9. Conclusions
There have been many proteins identified within breast
cancer EVs that give insight into the nature and severity
of the disease. These could serve as possible diagnostic
markers to be used in conjunction with current analytical
techniques. Both exosomes and MVs are key players in
the progression of cancer and elicit a multitude of cellular
responses within their target cells, at both the mRNA and
protein levels. There are multiple mechanisms by which
cancer cells avoid immune system recognition through EVs,
such as secretion of immunosuppressive proteins, inhibi-
tion of NK cell proliferation, or a decrease in CD8+ T-
cell cytotoxicity. Some targeted breast cancer therapies have
been investigated employing exosomes as a vehicle for drug
delivery, but due to the complex nature of EV-cell interac-
tions, additional studies need to be performed to achieve a
therapeutic strategy with a favorable therapeutic index using
an exosome approach. Tumors have the unique ability to
support their progression by using MVs and exosomes to
deliver procancerous transcripts and proteins, to both other
cancer cells and nontransformed cells. EVs are key players
within the cancer niche and are able to thrive in the acidic,
hypoxic environments common to tumors in order to confer
prometastatic phenotypes such as inflammation, migration,
and invasion. While there have been many advances in
recent years, future investigations involving EVs and their
contribution to tumor growth are crucial to the continued
understanding of cancer development.
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